Global Next Generation Sequencing Market - Industry Analysis and Forecasts 2016-2021

Report Code: HC-R-17-39 | Page Numbers: 161

Modern technologies assist in the sequencing of DNA and RNA much more quickly and cheaply than the Sanger sequencing and these have transformed the study of genomics and molecular biology. The arrival of next generation sequencing technologies has brought noteworthy changes in the sequencing process by providing speed, flexibility and reduced sequencing cost over thousand folds.

The next generation data analysis market is anticipated to see the fastest growth during the forecast period. With an expected increase in enactment of whole genome sequencing, the following data generation from sequencing projects is predicted to grow harmonically with the number of sequencing projects.

Advancements in pre-sequencing and NGS bioinformatics solutions, Rise in growth of personalized medicine and cloud computing, increasing incidences of infectious diseases, growth in global population, and cancer are few factors driving the market growth. In addition, anticipated decrease in the prices of genome sequencing due to development of rapid, high capacity whole genome sequencers by key players is expected to have a positive effect on market penetration rates over the few years. However, the storage and management of data generated by sequencing and its interpretation, hi...

Buy Now

"Get Notified On all out New and Upcoming Reports"

       on all the latest research reports

Modern technologies assist in the sequencing of DNA and RNA much more quickly and cheaply than the Sanger sequencing and these have transformed the study of genomics and molecular biology. The arrival of next generation sequencing technologies has brought noteworthy changes in the sequencing process by providing speed, flexibility and reduced sequencing cost over thousand folds.

The next generation data analysis market is anticipated to see the fastest growth during the forecast period. With an expected increase in enactment of whole genome sequencing, the following data generation from sequencing projects is predicted to grow harmonically with the number of sequencing projects.

Advancements in pre-sequencing and NGS bioinformatics solutions, Rise in growth of personalized medicine and cloud computing, increasing incidences of infectious diseases, growth in global population, and cancer are few factors driving the market growth. In addition, anticipated decrease in the prices of genome sequencing due to development of rapid, high capacity whole genome sequencers by key players is expected to have a positive effect on market penetration rates over the few years. However, the storage and management of data generated by sequencing and its interpretation, high reliability on grants & funding from the government and fall in capital expenditure from academic institutions are few factors hindering the growth of global next generation sequencing market.

At present, the next generation sequencing market is amalgamated with a few market players due to involvement of exceptionally complicated technologies and the low target audience for the systems. The market is dominated by Illumina, which accounted for the largest market share of approximately 70%. Other major players in the market include Thermo Fischer Scientific, Pacific Biosciences, Macrogen Inc.,Partek Inc., Genomatix Software GmbH, Perkin Elmer inc.,GATC Biotech Ag, Agilent Technologies Inc., Biomatters Ltd., BGI (Beijing Genomics Institute), Oxford Nanopore Technologies Ltd.,DNASTAR Inc., Knome Inc., and Qiagen N.V.
North America is currently the largest market for NGS. This is due to the increased awareness about the quick return of investments and accuracy. Asia-Pacific is one of the fastest growing segments. The NGS market can be segmented on the basis of Technology: Whole Genome Sequencing, Targeted Resequencing, Whole Exome Sequencing, RNA Sequencing, Chip Sequencing, De Novo Sequencing and Methyl Sequencing; Products: Instruments, Reagents & Consumables, and Services; End user: Hospitals & Healthcare Institutions, Academics, Biotech & Pharma Firms, and Others; Applications: Drug Discovery, Genetic Screening, Diagnostics, Personalized Medicine, Agriculture & Animal Research, Infectious Diseases among others; Geography: North America, Europe, APAC & RoW.
The major players operating in the NGS market are Illumina Inc. (U.S.), Thermo Fisher Scientific (U.S.), Hoffmann-La Roche Ltd (Switzerland), Pacific Biosciences (U.S.) Agilent Technologies (U.S.), BGI (Beijing Genomics Institute) (China), Qiagen (Netherlands), Biomatters Ltd (New Zealand), and Genomatix Software GmbH (Germany).
1. INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 RESEARCH METHODOLOGY
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
3.1 MARKET DEFIANTION
3.2 MARKET DRIVERS
3.2.1 INCREASING APPLICATIONS IN THE CLINICAL DIAGNOSIS
3.2.2 SPEED, COST AND ACCURACY TO SPUR THE MARKET GROWTH
3.2.3 EFFICIENT REPLACEMENT FOR TRADITIONAL TECHNOLOGIES (MICROARRAYS)
3.2.4 DRUG DISCOVERY APPLICATIONS DEMANDING NGS TECHNOLOGY
3.3 MARKET RESTRAINTS
3.3.1 LEGAL AND ETHICAL ISSUES
3.3.2 INTERPRETATION OF COMPLEX DATA
3.3.3 LACK OF SKILLED PROFESSIONALS
4. PORTER'S FIVE FORCES
4.1 BARGAINING POWER OF SUPPLIERS
4.2 BARGAINING POWER OF BUYERS
4.3 DEGREE OF COMPETITION:
4.4 THREAT OF SUBSTITUTION:
4.5 THREAT OF NEW ENTRANTS:
5. GLOBAL MARKET SEGMENTATION
5.1 GLOBAL NEXT GENERATION SEQUENCING MARKET
5.1.1 BY TECHNOLOGY
5.1.1.1 WHOLE GENOME SEQUENCING
5.1.1.2 TARGETED RESEQUENCING
5.1.1.3 WHOLE EXOME SEQUENCING
5.1.1.5 CHIP SEQUENCING
5.1.1.6 DE NOVO SEQUENCING
5.1.1.7 METHYL SEQUENCING
5.1.2 BY PRODUCTS
5.1.2.1 INSTRUMENTS
5.1.2.2 REAGENTS & CONSUMABLES
5.1.2.3 SERVICES
5.1.3 BY END USERS
5.1.3.1 HOSPITALS & HEALTHCARE INSTITUTIONS
5.1.3.2 ACADEMICS
5.1.3.3 BIOTECHNOLOGY:
5.1.3.4 PHARMACEUTICALS:
5.1.4 BY APPLICATION
5.1.4.1 DRUG DISCOVERY/PERSONALIZED MEDICINE
5.1.4.2 GENETIC SCREENING:
5.1.4.3 INFECTIOUS DISEASES / DIAGNOSTICS:
5.1.4.4 AGRICULTURE AND ANIMAL RESEARCH
5.1.4.5 OTHERS:
5.1.5 BY GEOGRAPHY
5.1.5.1 NORTH AMERICA
5.1.5.1.1 USA
5.1.5.1.2 CANADA
5.1.5.1.3 MEXICO
5.1.5.2 EUROPE
5.1.5.2.1 UK
5.1.5.2.2 GERMANY
5.1.5.2.3 FRANCE
5.1.5.2.4 ITALY
5.1.5.2.5 SPAIN
5.1.5.3 ASIA PACIFIC
5.1.5.3.1 CHINA
5.1.5.3.2 JAPAN
5.1.5.3.3 INDIA
5.1.5.3.4 AUSTRALIA
5.1.5.3.5 OTHERS
5.1.5.4 ROW
6. COMPETITIVE LANDSCAPE
6.1 MERGERS AND ACQUISITIONS
6.2 AGREEMENTS, COLLABORATIONS & PARTNERSHIPS
6.3 NEW PRODUCT LAUNCHES
7. COMPANY PROFILES
7.1 ROCHE HOLDING AG
7.1.1 OVERVIEW:
7.1.2 BUSINESS STRATEGY:
7.1.3 PRODUCTS & SERVICES:
7.1.4 FINANCIALS:
7.1.5 SWOT ANALYSIS:
7.1.6 ANALYST VIEW:
7.2 AGILENT TECHNOLOGIES
7.2.1 OVERVIEW:
7.2.2 BUSINESS STRATEGY:
7.2.3 PRODUCTS:
7.2.4 FINANCIALS:
7.2.5 SWOT ANALYSIS:
7.2.6 ANALYST VIEW:
7.3 BEIJING GENOMICS INSTITUTE
7.3.1 OVERVIEW
7.3.2 SERVICES
7.3.3 ANALYST VIEW
7.4 BIOMATTERS LTD.
7.4.1 OVERVIEW
7.4.2 PRODUCTS & SERVICES:
7.4.3 ANALYST VIEW:
7.5 QIAGEN NV (QGEN) -NASDAQGS
7.5.1 OVERVIEW
7.5.2 BUSINESS STRATEGY
7.5.3 PRODUCTS & SERVICES
7.5.4 FINANCIALS
7.5.5 SWOT ANALYSIS
7.5.6 ANALYST VIEW
7.6 DNASTAR, INC.
7.6.1 OVERVIEW
7.6.2 PRODUCTS
7.6.3 ANALYST VIEW
7.7 GATC Biotech
7.7.1 OVERVIEW
7.7.2 BUSINESS STRATEGY
7.7.3 PRODUCTS & SERVICES
7.7.4 ANALYST VIEW
7.8 GENOMATIX SOFTWARE GMBH
7.8.1 OVERVIEW
7.8.2 BUSINESS STRATEGY
7.8.3 PRODUCTS & SERVICES
7.8.4 ANALYST VIEW
7.9 ILLUMINA INC. (ILMN) -NASDAQGS
7.9.1 OVERVIEW
7.9.2 BUSINESS STRATEGY
7.9.3 PRODUCTS & SERVICES
7.9.4 FINANCIALS
7.9.5 SWOT ANALYSIS
7.9.6 ANALYST VIEW
7.10 KNOME, INC.
7.10.1 OVERVIEW
7.10.2 BUSINESS STRATEGY
7.10.3 PRODUCTS & SERVICES
7.10.4 ANALYST VIEW
7.11 THERMO FISHER SCIENTIFIC INC.
7.11.1 OVERVIEW
7.11.2 BUSINESS STRATEGY
7.11.3 PRODUCTS
7.11.4 FINANCIALS:
7.11.5 SWOT ANALYSIS
7.11.6 ANALYST VIEW
7.12 MACROGEN INC.
7.12.1 OVERVIEW
7.12.2 BUSINESS STRATEGY
7.12.3 Products & Services
7.12.4 FINANCIALS
7.12.5 SWOT ANALYSIS
7.12.6 ANALYST VIEW
7.13 OXFORD NANOPORE TECHNOLOGIES
7.13.1 OVERVIEW
7.13.2 PRODUCTS & SERVICES
7.13.3 ANALYST VIEW
7.14 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
7.14.1 OVERVIEW
7.14.2 BUSINESS STRATEGY
7.14.3 PRODUCTS & SERVICES
7.14.4 FINANCIALS:
7.14.5 ANALYST VIEW
7.15 PARTEK INC.
7.15.1 OVERVIEW
7.15.2 PRODUCTS & SERVICES
7.15.3 ANALYST VIEW
7.16 PERKINELMER INC. (PKI) -NYSE
7.16.1 OVERVIEW
7.16.2 BUSINESS STRATEGY
7.16.3 PRODUCTS & SERVICES
7.16.4 FINANCIALS
7.16.5 SWOT ANALYSIS
7.16.6 ANALYST VIEW
Modern technologies assist in the sequencing of DNA and RNA much more quickly and cheaply than the Sanger sequencing and these have transformed the study of genomics and molecular biology. The arrival of next generation sequencing technologies has brought noteworthy changes in the sequencing process by providing speed, flexibility and reduced sequencing cost over thousand folds.

The next generation data analysis market is anticipated to see the fastest growth during the forecast period. With an expected increase in enactment of whole genome sequencing, the following data generation from sequencing projects is predicted to grow harmonically with the number of sequencing projects.

Advancements in pre-sequencing and NGS bioinformatics solutions, Rise in growth of personalized medicine and cloud computing, increasing incidences of infectious diseases, growth in global population, and cancer are few factors driving the market growth. In addition, anticipated decrease in the prices of genome sequencing due to development of rapid, high capacity whole genome sequencers by key players is expected to have a positive effect on market penetration rates over the few years. However, the storage and management of data generated by sequencing and its interpretation, high reliability on grants & funding from the government and fall in capital expenditure from academic institutions are few factors hindering the growth of global next generation sequencing market.

At present, the next generation sequencing market is amalgamated with a few market players due to involvement of exceptionally complicated technologies and the low target audience for the systems. The market is dominated by Illumina, which accounted for the largest market share of approximately 70%. Other major players in the market include Thermo Fischer Scientific, Pacific Biosciences, Macrogen Inc.,Partek Inc., Genomatix Software GmbH, Perkin Elmer inc.,GATC Biotech Ag, Agilent Technologies Inc., Biomatters Ltd., BGI (Beijing Genomics Institute), Oxford Nanopore Technologies Ltd.,DNASTAR Inc., Knome Inc., and Qiagen N.V.
North America is currently the largest market for NGS. This is due to the increased awareness about the quick return of investments and accuracy. Asia-Pacific is one of the fastest growing segments. The NGS market can be segmented on the basis of Technology: Whole Genome Sequencing, Targeted Resequencing, Whole Exome Sequencing, RNA Sequencing, Chip Sequencing, De Novo Sequencing and Methyl Sequencing; Products: Instruments, Reagents & Consumables, and Services; End user: Hospitals & Healthcare Institutions, Academics, Biotech & Pharma Firms, and Others; Applications: Drug Discovery, Genetic Screening, Diagnostics, Personalized Medicine, Agriculture & Animal Research, Infectious Diseases among others; Geography: North America, Europe, APAC & RoW.
The major players operating in the NGS market are Illumina Inc. (U.S.), Thermo Fisher Scientific (U.S.), Hoffmann-La Roche Ltd (Switzerland), Pacific Biosciences (U.S.) Agilent Technologies (U.S.), BGI (Beijing Genomics Institute) (China), Qiagen (Netherlands), Biomatters Ltd (New Zealand), and Genomatix Software GmbH (Germany).

Download Sample

Just fill the short form below to get the sample

Don’t like forms? Give us a call. U.S. +1(973)805-7440 (International) Email us at: amit@ceskaa.com